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Summary
Syndecan-1 (Sdc1) is a transmembrane heparan-sulfate proteoglycan, an extracellular matrix receptor and a cell-ma-
trix adhesion organiser, included in adhesion of all cell’s contact surfaces. It integrates different cellular signals and signals 
between growth factors, and modulates cell proliferation, carcinogenesis, migration and angiogenesis. Cellular motion and 
invasion first require loss of the Sdc1. Sdc1 expression is lost shortly before the cell changes shape or location, which de-
crease adhesiveness but enhance cellular mobility and their invasive potential. Releasing of Sdc1 from the cell surface (shed-
ding) enables tumor growth and metastasizing. Such change of the Sdc1 expression is of crucial value for transition of inva-
sive breast carcinoma to metastatic phenotype, and it is a part of epithelial-to-mesenchymal transition (EMT). Molecules 
included in EMT are potential targets for anticancer pharmacotherapy and control of tumor metastasizing. Maybe proteo-
lytic conversion from insoluble (membrane bound coreceptor) to soluble Sdc1 is trigger for turning of proliferative phase of 
breast cancer to invasive one, which can also be of potential diagnostic-therapeutic benefit. Stromal Sdc1 expression means 
not merely the simple fixation of the released Sdc1 from the epithelial cells to the stromal, but also autochthonous Sdc1 
synthesis in reactive stromal fibroblasts. By interacting with heparin-binding growth factors, Sdc1 accumulates in the stro-
ma and can contribute to proliferation of invasive tumor stroma and neoangiogenesis. In more than 70% of breast carcino-
mas Sdc1 is induced in stromal fibroblasts, with the significant difference in its expression between stroma of malignant and 
non-malignant breast tissue. Although part of breast cancers loses Sdc1, in most of them it is expressed or over-expressed, 
and its expression is associated with a poorer response of this cancer to chemotherapy. Studies about prognostic significance 
of Sdc1 in breast cancer have shown unequal results, which refers to the need for new researches on this subject.
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INTRODUCTION
Syndecan-1 (Sdc1) is a transmembrane hepa-
ran sulfate proteoglycan (HSPG), an extracellular 
matrix (ECM) receptor and cell-matrix adhesion 
organiser, active participant in all important cel-
lular and tissue processes such as inflammation, 
repair, immune response, metabolism, apoptosis, 
carcinogenesis and metastasizing, insurer of the 
integration of different cellular signals and signals 
between growth factors, and modulator of the cell 
proliferation, migration, invasion and angiogene-
sis (1-6). Also known as CD138, it is expressed in 
normal and malignant tissue; predominantly on/
in epithelial cells, but it can be found in mesenchy-
mal cells during their development and in the 
stroma of different malignant tumors, at various 
stages of activation and differentiation of normal 
lymphoid cells (i.e. in centrocytes, not centro-
blasts), in normal mature plasma cells and atypi-
cal plasma cells in multiple myeloma (MM) (7). It 
is mostly expressed on the surfaces of adherent 
epithelial cells; e.g. during differentiation, stratifi-
cation and maturation of keratinocytes, when in-
tercellular adhesion is enhanced, the quantity of 
Sdc1 on cells surfaces is increased in comparison 
to non-stratified cells, meaning it is included in 
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the adhesion process on all contact cell surfaces 
(8,9). Most probable Sdc1 mediates the adhesion 
of mesenchymal cells too; after the disaggregation 
of mesenchymal cells in vitro, it was found to be 
intensely expressed on cells that re-aggregated 
(10). Interestingly, the Sdc1 expression, similar to 
the expression of other adhesion molecules, such 
as cadherin, is lost shortly before the cell changes 
shape or location (11,12). Similar processes have 
been shown during malignant transformation and 
tumor progression, so probable the cellular mo-
tion and invasion first require loss of Sdc1 and de-
crease in cellular adhesion capacity.
The prognostic value of Sdc1 was investigat-
ed in various carcinomas - including breast, 
colorectal, gastric, pancreatic and liver, prostate 
and bladder, lung, endometrium and ovary, head 
and neck, MM. Sdc1 loss is mainly associated with 
aggressive tumor phenotype and poor prognosis 
of the disease. Similarly, the reduction of Sdc1 ex-
pression in carcinomas is mostly associated with 
histological (de)differentiation and/or tumor 
grade. In poorly differentiated tumors, there is of-
ten a loss of expression, although different histo-
logical types as well as carcinomas of different 
body sites show differences in Sdc1 expression 
and its meaning; for example, in planocellular car-
cinoma of the head and neck the Sdc1 expression 
means a better prognosis, while – according to cer-
tain studies - its high level in breast cancer corre-
lates with a more aggressive phenotype and poor 
prognosis. Inconsistent and contradictory results 
indicate the involvement of other factors in the 
molecular oncogenesis, which are necessary for 
understanding Sdc1 expression.
The role of Sdc1, ECM and stromal fibroblasts  
in breast cancer initiation and progression
The significance of the Sdc1 in a breast carci-
noma has been more frequently the subject of inter-
est - sometimes from an exclusive narrow molecu-
lar aspect (13) and sometimes from the clinical-
prognostic aspects (14). In tumor progression, Sdc1 
makes an impact on several levels, and it can act as 
a supressor and as a tumor-growth promoter, de-
pending on the type of tumor and localization of 
proteoglycan - on the cell surface or released in the 
microenvironment or in both locations.
In a healthy breast and physiological condi-
tions, the gene expressions for Sdc1, syndecan-4 
(Sdc4) and decorin is significantly lower in the lu-
teal phase of the menstrual cycle compared to the 
follicular phase, which is a possible result of ovar-
ian hormones activity and is the basis for further 
studies, for example in women on hormone thera-
py or women with breast cancer (15). Increased 
progesterone in the luteal phase of the cycle inter-
acts with growth factors increasing their synergis-
tic and inhibitory effects, thus affecting the ECM 
structure (16). Healthy breast stroma in compari-
son to the tumour stroma in postmenopausal 
women shows significantly lower Sdc1 - its value 
in malignant stroma being >10x higher, with al-
most extreme Sdc1 redistribution from the epithe-
lium to the stroma (17). By comparing the mam-
mographically detected healthy breast tissue den-
sity with the Sdc1 expression in postmenopausal 
women with breast cancer, a strong correlation 
was found between the epithelial estrogen recep-
tor-alpha (ER-alpha) and Sdc1 found in the stroma 
of mammographically detected high density tis-
sue, not recorded in low density tissue (18). The 
results of these two studies suggest that a signifi-
cant increase of Sdc1 in malignant stroma and the 
redistribution of Sdc1 in the direction of epitheli-
um → stroma are in connection with the biological 
baseline of the disease, which is also reflected in 
the breast tissue density (17,18). Glandular (epi-
thelial) Sd1 expression is lower in malignant 
breast tumors than in benign or normal breast tis-
sue in premenopausal women, with the opposite 
findings in the stroma, as well with the change of 
Sdc1 localization from epithelial to stromal cells in 
malignant tissue (19).
The loss of Sdc1 expression reduces cell ad-
hesion, increases the invasive potential and dereg-
ulates the growth of epithelial breast cells. Stanley 
et al. have demonstrated a significantly lower 
Sdc1 expression on malignant cells of the invasive 
ductal carcinomas (IDCs) in comparison to Sdc1 
expression in healthy tissue and epithelial-stromal 
tumors (20). A significant difference was found 
between Sdc1 expression in malignant and non-
malignant stromal breast tissue. It was strongly 
expressed in the stroma and on the border of epi-
thelium-stroma in IDCs, but absent in the stroma 
of healthy tissue and epithelial-stromal tumors. 
Breast stroma is important in response modula-
tion of epithelial cells to sex hormones, and ECM 
proteoglycans have an important role in signal-
ling between components of different tissues. By 
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interacting with heparin-binding growth factors 
such as fibroblast growth factor-2 (FGF-2), Sdc1 
accumulates in the stroma and can contribute to 
angiogenesis and proliferation of invasive tumor 
stroma. Such a change in Sdc1 expression is of cru-
cial importance in IDC transition to a metastatic 
phenotype. The induction of Sdc1 in the stroma is 
connected to expression loss in malignant epithe-
lial cells (20).
In more than 70% of breast carcinomas Sdc1 
is induced in stromal fibroblasts. Maeda et al. have 
shown that Sdc1 from stromal fibroblasts stimu-
lates the proliferation of malignant epithelial cells 
in mice, with significant acceleration of tumor 
growth and further growth increase (for 88%) in 
case of severe expression (21). Increased expres-
sion of stromal Sdc1 was also connected to signifi-
cant density increase of smaller (to 36%) and larg-
er (up to 15%) blood vessels. A similar result was 
found in 207 specimens of human breast cancer 
(21). Sdc1 is necessary for the growth of reactive 
stroma. By inoculating the culture of a highly in-
vasive breast cancer cell line into the embryonic 
fibroblast co-culture in mice, Maeda et al. have in-
duced Sdc1 expression, which was absent follow-
ing the inoculation of less invasive malignant and 
normal cell lines. Stroma growth has been com-
pletely stopped by inserting a gene for mutated 
Sdc1 that lacks a heparan sulfate locus. Sdc1 in-
duction into stromal fibroblasts stimulates multi-
plication of malignant epithelium, suggesting in-
teraction of malignant cells and surrounding stro-
ma dependent on the activity of glycosylated Sdc1 
(22). Stromal Sdc1 expression means the occur-
rence of strong immunoreactivity in reactive stro-
mal cells of invasive tumors and their autochtho-
nous Sdc1 synthesis, not merely the simple fixa-
tion of the released Sdc1 from the epithelial cells 
to the stromal (23). Spindle cells of connective tis-
sue with myofibroblastic differentiation that may 
contribute to tumor cell dedifferentiation and me-
tastases development in breast, lung, colon and 
bladder cancer, show high Sdc1 expression (23).
Although part of breast cancer loses Sdc1, in 
most carcinoma it is expressed or over-expressed. 
Cells of poorly differentiated tumors contain intra-
cellular Sdc1; in vitro they internalise the intact Sdc1 
from the surface where it gradually accumulates 
into intracellular lysosomes where it breaks down, 
while the cells of well differentiated tumors retain 
most of Sdc1 on the surface, but also internalise it to 
lysosomes (24). The Sdc1 ectodomain regulates the 
matrix-dependent signalling. Increases in the level 
of surface Sdc1 in the culture of breast cancer cells, 
changes the signalling dependent on the matrix, 
which can result in weaker cell cohesion and inva-
sion in the early tumorigenesis (25). It is not com-
pletely clear how the released Sdc1 accelerates tu-
mor growth. Maybe Sdc1 ectodomain affects the 
extracellular proteolysis - necessary for tumor inva-
sion and metastasizing, similar to its activity in 
acute wound fluids (26). Sdc1 over-expression pro-
motes metastasizing of breast cancer cells to the 
brain via cytokines, which can modulate blood-
brain barrier in vitro (27).
By releasing Sdc1 from the cell surface - 
growth, angiogenesis and tumor metastasizing 
are made possible. Heparanase enzyme on tumor 
cells is a strong promoter of tumor progression 
and metastasizing. It regulates the level and loca-
tion of Sdc1 in the tumor microenvironment by 
increasing its synthesis and release (28). Such reg-
ulation of Sdc1 by heparanase has been demon-
strated in MM and breast cancer cell lines, where 
both markers act synergistically in the stimulation 
of an aggressive tumor phenotype. By removing 
heparan sulfate from the cell surface by a bacterial 
heparitinase, dramatically accelerates the release 
of Sdc1, which means that the effects of heparan-
ase on Sdc1 expression in tumor cells are at least, 
in part, mediated by the reduction in the size of 
Sdc1 heparan sulfate chains (28).
The two forms of Sdc1, the membrane bound 
coreceptor and the soluble effector form, are ca-
pable of binding the same ligands, but with differ-
ent roles in different stages of breast cancer and its 
progression (29). It is possible that the proteolytic 
conversion of insoluble to soluble form is a trigger 
to turn the proliferative stage of breast cancer in 
the invasive, which could be useful in the diagno-
sis and potential glycosaminoglycan treatment of 
this cancer (29). Both - the composition and chang-
es in the proteoglycan structure during malignant 
transformation, affect the adhesive abilities and 
mitotic activity of tumor cells. Changes in the ex-
pression intensities of Sdc1, decorins and lumi-
cans in tumor breast tissue can induce the mitotic 
activity of tumor cells (30). A strong negative cor-
relation of Sdc1 with ECM components, especially 
collagen IV and tenascin, confirms its role in the 
remodelling of breast cancer tissue and its signifi-
cance in tumor progression (31). As well, Sdc1 
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modulates assembly of 3D fibrillar ECM - directly 
by interacting with fibronectin via its heparan sul-
fate chains and by activating integrin αvβ3 via its 
ectodomain; such amazing rearrangement of ECM 
in terms of alignment, creates a kind of stromal 
highways for spreading of malignant epithelial 
cells that certainly accelerate their progression 
and metastasizing, but also may lead to new stro-
ma-targeted therapy by altering an invasion-per-
missive to invasion-restrictive tumor microenvi-
ronment in breast cancer (32).
Sdc1 and epithelial-to-mesenchymal-transition  
in breast cancer
Tumor growth is evidence of changes to its 
structure through specific adjustment of tissue 
called epithelial-to-mesenchymal transition (EMT), 
but it also occurs in physiological processes of 
growth and development, when epithelial cells 
exhibit reduced adhesion, increased mobility and 
acquire mesenchymal features similar to fibro-
blasts (33,34). The disruption of intercellular con-
nections and an increase in mobility of cells being 
released from the original epithelium are there-
fore essential. Such a phenotype similar to mesen-
chyme facilitates migration, but also invasion, dis-
semination and metastasis of malignant cells. 
EMT has a critical role in malignant transforma-
tion and progression by providing the initial tu-
mor with invasive and metastatic traits. Although 
the molecular mechanism of EMT is not fully 
known, several signalling molecules that poten-
tially induce it have been identified (growth fac-
tors, tyrosine kinase receptors, β-catenin, integ-
rins), as well as signalling pathways (e.g. phos-
phatidylinositol 3’ kinase/Akt axis) leading to 
Figure 1a. Strong epithelial (both membranous  
and cytoplasmic) and absence of stromal Sdc1 expression, 
IDC (IHC, x200)
Figure 1b. Strong epithelial (both membranous  
and cytoplasmic) Sdc1 expression, with the accumulation  
of Sdc1 in the intraluminal necrotic tumor mass, IDC  
(IHC, x400)
Figure 1c. Moderate to strong epithelial Sdc1  
expression - membranous and focally strong  






 reduction or loss of the E-cadherin adhesion mole-
cule (33,34). Gen E-cadherin is inactivated in 
 diffuse carcinomas such as lobular breast carcino-
ma and diffuse gastric cancer, where malignant 
cells within the entire tumor mass lose more of 
their epithelial properties and become highly in-
vasive (33). However, a reduction of E-cadherin is 
also seen in solid non-diffuse tumors on epitheli-
al-stromal border where malignant cells invade 
individually. This would mean that the loss of E-
cadherin and EMT can be reversible processes, 
probably regulated by the tumor microenviron-
ment. Malignant epithelial cells that passed the 
transition to the mesenchymal phenotype during 
the invasion, could again obtain E-cadherin ex-
pression and epithelial (cohesive) features in sec-
ondary focuses (33). Thanakit et al. also point to 
the possibility of E-cadherin re-expression due to 
it being highly expressed in metastatic axillary 
nodes in breast cancer (35). During the transition 
from epithelial to less differentiated mesenchy-
imal phenotype or during EMT, the malignant 
cells lose Sdc1 as well. The change in Sdc1 expres-
sion from malignant epithelial to reactive stromal 
cells was found during progression of various car-
cinomas including breast cancer (36-38).
Figure 2a. Moderate to focally strong epithelial, and focally weak to moderate stromal Sdc1 expression, IDC (IHC, x100)
Figure 2b. Moderate stromal and absence of epithelial (loss) Sdc1 expression, IDC (IHC, x200)
Figure 3a. Weak to moderate epithelial Sdc1 expression, ILC (IHC, x400)







The critical feature of EMT is reduced expres-
sion of both markers - E-cadherin and Sdc1 on tu-
mor cells (36,37). E-cadherin gene, otherwise re-
sponsible for epithelial cell cohesion, is absent in 
80-100% of invasive lobular carcinomas (ILCs), 
and its inactivation is an early molecular event in 
its oncogenesis (39). In our research about differ-
ences in Sdc1 expression between IDCs and ILCs, 
we suggested, among other things, a possible 
stronger association between Sdc1 and E-cadherin 
in lobular than in ductal cancers, with the assump-
tion that somewhat weaker stromal Sdc1 expres-
sion in lobular tumors is probably connected with 
a greater E-cadherin loss, i.e. that tumor cells of 
lobular carcinomas lose more Sdc1 during EMT 
than ductal malignant cells undergoing EMT (38). 
It may be supported by the fact that in our study 
the epithelium of both primary carcinomas ex-
pressed Sdc1 in exactly the same way - in 90% of 
cases. Therefore, it unevenly loses Sdc1 during 
EMT (which is probably linked with a loss of E-
cadherin as described), or the induction of Sdc1 is 
possible weaker in the stroma of lobular cancers. 
As previously mentioned, Sdc1 is partly synthe-
sized in the stroma itself, i.e. in the stromal fibro-
blasts, that raises the hypothesis of its possible 
lower synthesis in the stromal fibroblasts of ILCs. 
This can be supported by our results of Sdc1 ex-
pression distribution in primary ILCs, according 
to which the stroma of ILC often, or - in as many 
as 40%, did not show even a weak Sdc1 expression 
(38) (Figures 1a, 1b and 1c; 2a and 2b; 3a and 3b). 
All molecules included in EMT are potential tar-
gets for pharmacological treatment and open new 
possibilities for tumor metastasis control (33).
Some more recent morphological  
and clinical-prognostic studies about Sdc1  
in breast cancer
The significance of Sdc1 in breast ductal car-
cinoma in situ (DCIS) is not known enough. Tie-
mann et al. explored the Sdc1 expression in 127 
DCIS cases of different nuclear grades and con-
cluded that nuclear grade and Sdc1 tissue local-
ization correlate significantly, that is, the tissue 
localization of the Sdc1 in DCISs of different 
grades is significantly divergent, which suggests 
its specific influence on DCIS biopathology and 
progression (40). Expression of Sdc1, E-cadherin 
and c-Met (a receptor for the hepatocyte growth 
factor) is associated with the promoters of tumor 
angiogenesis and lymphangiogenesis in breast 
DCIS (41). 72% of DCISs show strong Sdc1 expres-
sion (significantly more often DCISs compared to 
the tumors with an invasive component), with a 
correlation between Sdc1 expression level and 
HER2/neu. E-cadherin expression is related to the 
expression of Sdc1 and c-Met. The co-expression 
of these markers may mean parallel activation of 
different signalling pathways in cell proliferation 
and neoangiogenesis (receptor tyrosine kinase, 
nuclear transcription factor), but also a new, effec-
tive treatment approach with multiple target mol-
ecules in the initial progression of breast cancer 
(41). Extracapsular tumor expansion outside the 
affected axillary lymph nodes, significantly in-
creases the risk of local recurrences and distant 
metastases in breast cancer, and is associated with 
a greater number of metastatic nodes and larger 
primary tumors (35). Both - Sdc1 and E-cadherin 
(its re-expression?) are increasingly expressed in 
metastatic lymph nodes, indicating the coordinat-
ed action of both markers in tumor aggression and 
invasion of the axillary tissue (35).
With a key role in the development and pro-
gression of breast cancer, estrogens have multiple 
effects on ECM molecules. Sdc1 and Sdc4 are ex-
cessively expressed in ER negative, highly prolif-
erative breast carcinoma (42). Baba et al. have 
showed a significant correlation between the ex-
pression of Sdc1, Sdc4 and glypican-1 (besides 
syndecans, one of the main cell surface HSPGs) 
with a cell proliferation marker - Ki67. Sdc1 and 
Sdc4 expressions - ranging from total loss to strong 
expression, correlated with a negative ER, grade 
and size of the primary tumor; Sdc1 was a predic-
tor of clinical behaviour, but not an independent 
prognostic marker. A strong correlation between 
surface HSPGs and Ki67 confirms their role in tu-
mor growth regulation. The expression of syn-
decans and a negative ER are associated with an 
aggressive, ER-negative type of breast cancer (42).
Leivonen et al. have evaluated the prognostic 
value of Sdc1 expression in 200 samples of inva-
sive breast cancer, with a median follow-up peri-
od of 17 years (43). Epithelial Sdc1 expression ap-
peared in 61% of tumors, while stromal Sdc1 ex-
pression showed 67% of tumors. Epithelial 
expression was associated with a negative ER sta-
tus, and stromal expression with positive ER. 65% 
of patients with tumors showing epithelial Sdc1 
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expression have lived for ten years, and 82% of pa-
tients with the loss of epithelial expression. 66% of 
patients with positive stromal Sdc1 expression 
have lived for ten years, and 83% of those with 
negative stromal Sdc1 expression. Only 56% of pa-
tients with both expressions have lived for ten 
years, and 78% of patients with other combina-
tions of epithelial-stromal Sdc1 expression. Only 
the axillary metastases and tumor size have shown 
as significant predictors of survival. The simulta-
neous epithelial-stromal Sdc1 expression may 
mean a poorer prognosis for breast cancer, and 
contrary to the results of other similar studies, the 
loss of the epithelial Sdc1 is associated with a sig-
nificantly more favorable prognosis (43).
Both - epithelial and stromal Sdc1 expressions 
have prognostic value in various carcinomas, in-
cluding breast cancer (43-45). Loussouarn et al. re-
evaluated the prognostic significance of Sdc1 in 
breast IDCs, by comparing Sdc1 expression with 
clinicopathological parameters and relapse-free 
survival (RFS) of patients (45). They found a sig-
nificant correlation between loss of epithelial and 
stromal Sdc1 expression with high histological 
grade and aggressive tumors. They associated a 
strong epithelial Sdc1 expression with a low grade 
and well differentiated breast carcinomas, and a 
reduction of expression with poorly differentiated 
ones. The prognosis for the tumors with epithelial 
Sdc1 expression, exclusively or together with a 
stromal is excellent, while it is bad for those with-
out an epithelial expression. The loss of epithelial 
Sdc1 expression correlated with RFS and showed 
prognostic value (45). Barbareschi et al. identified 
the increased Sdc1 expression in 42% of breast can-
cers, mostly in large tumors, with a high grade and 
high mitotic index, ER/progesterone receptor (PR) 
negative and HER2/neu over-expression, associat-
ed it with an aggressive phenotype and poor prog-
nosis, while the stromal expression was not ob-
served from the prognostic point of view (44). 
Malek-Hosseini et al. determined a positive corre-
lation between the soluble Sdc1 levels (from breast 
cancer patients’ sera) and a tumor size, which also 
suggest the importance of the Sdc1 different forms 
(cell-bound and soluble) in the progression of this 
carcinoma (46).
Sdc1 expression is associated with a poorer 
response of breast cancer to chemotherapy. Götte 
et al. have demonstrated the influence of Sdc1 ex-
pression and its expression level to the response to 
the neoadjuvant chemotherapy in locally ad-
vanced breast cancer (47). Sdc1 was expressed in 
43.2% of carcinoma, more often in the ductal his-
tological type. The response to therapy was re-
duced in Sdc1-positive patients, none of whom 
showed complete remission. None of the tumors 
sensitive to chemotherapy have shown a strong 
Sdc1 expression, while it was found in 20% of re-
sistant tumors (47). Breast cancer stroma of preop-
eratively treated patients varies from those of un-
treated patients; Sdc1 was significantly reduced 
and collagen-IV elevated in the tumor stroma of 
preoperatively treated patients. Tenascin-C was 
elevated in the stroma of patients with progres-
sive disease, while smooth muscle actin did not 
show significant difference in expression (48).
Kind et al. analyzed separately membranous, 
cytoplasmic and stromal Sdc1 expression in 1535 
breast cancers; loss of membranous and the pres-
ence of cytoplasmic and stromal Sdc1 expression 
were-to a variable degree-associated with high pT, 
high grade, nodal metastases, ER/PR negative, 
HER2neu positive and poor overall survival (49). 
The best prognosis had patients with stromal Sdc1 
positivity and cytoplasmic negativity, and the 
worst prognosis patients with opposite findings - 
cytoplasmic positivity and stromal negativity, so 
they connected cytoplasmic Sdc1 expression with 
aggressive, and stromal with a more favourable 
outcome (49). Similar correlations between Sdc1 
over-expression with main prognostic factors and 
poor overall survival in breast cancer were ob-
tained by other authors (50,51).
In our study, we determined the Sdc1 expres-
sion in malignant epithelium and stroma of 30 
ILCs and 30 IDCs, and in the axillary metastases 
of the latter, comparing them with each other and 
with some clinical and histological parameters 
(38). Sdc1 was altogether expressed in the tumor 
epithelium of 90% carcinomas of both histological 
types, most commonly in the stroma of both types 
as well, but absent in the stroma of 40% ILCs. It 
was also expressed in the tumor epithelium of as 
many as 86.7% IDC metastases (strongly in 50%), 
while the stroma of 46.7% metastases was nega-
tive. In primary IDCs, a negative correlation of 
epithelial Sdc1 and PR expression was detected, 
and in ILCs a positive correlation of stromal Sdc1 
and histological grade. Axillary IDC metastases 
showed a negative correlation of Sdc1 from tumor 
epithelium with the patient age and ER/PR of pri-
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mary tumors, and a positive correlation of Sdc1 
from metastatic stroma with number of primary 
tumor foci or a negative correlation with PR ex-
pression in primary tumors (38). However, the 
topics that associate Sdc1 expression in the prima-
ry breast cancers and its metastases are insuffi-
cient, as well as the significance of the possible as-
sociations for the oncology practice. Indeed, ac-
cording to my knowledge and by reviewing the 
available relevant literature, such researches have 
not been found. Our study showed an identical 
overall epithelial without a statistically significant 
difference in stromal Sdc1 expression in two of the 
most common types of breast cancer - ductal and 
lobular, proved the role of Sdc1 in the progression 
of both histological types and in the development 
of metastatic potential of ductal cancer, but also 
determined that strong Sdc1 expression in region-
al IDC metastases is a highly potent source of fur-
ther tumor progression (38).
CONCLUSION
The control of the cell adhesion is partly me-
diated by the Sdc1, and understanding the under-
lying molecular mechanisms - besides the physi-
ological phenomena of growth and development 
- is necessary in the pathological processes such as 
the tumor cell invasion and metastasizing. There 
are numerous studies on the Sdc1 in the maligno-
mas of different origins and different body sites, 
very often with different, even controversial re-
sults. Its role and meaning in a breast cancer has 
been frequently investigated from the genetic-mo-
lecular and clinical-prognostic aspects, but there 
are still many unexplored niches in the context of 
its interactions with the microenvironment and 
many other molecular allies or opportunists. New 
research on histologically different types of breast 
cancer will more precisely define the function and 
significance of Sdc1 in their initial carcinogenesis, 
progression and metastasizing, as well as illumi-
nate and link Sdc1 interactions with other known 
or possible new participants of the extremely de-
manding oncological pathology.
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Sažetak
VRIJEDNOST IMUNOHISTOKEMIJSKOG ODREĐIVANJA SYNDECANA-1 U KARCINOMU DOJKE
I. Miše
Syndecan-1 (Sdc1) je transmembranski heparan-sufatni proteoglikan, receptor za ekstracelularni matriks, organizator 
adhezije stanica-matriks, uključen u adheziju na svim kontaktnim staničnim površinama. Integrira različite stanične signale 
i signale među čimbenicima rasta te modulira staničnu proliferaciju, kancerogenezu, migraciju i angiogenezu. Stanično 
kretanje i invazija prvo zahtjevaju gubitak Sdc1. Ekspresija Sdc1 se gubi neposredno prije nego stanica promijeni oblik ili 
lokaciju, što smanjuje adhezivnost a povećava staničnu mobilnost i invazivni potencijal. Otpuštanjem Sdc1 s površine stani-
ca (shedding) omogućava se rast tumora i metastaziranje. Takva promjena ekspresije Sdc1 od presudne je važnosti u tranzi-
ciji invazivnih karcinoma dojke u metastatski fenotip i prati epitelno-mezenhimalnu tranziciju (EMT). Molekule uključene 
u EMT-u potencijalni su ciljevi za farmakoterapiju i kontrolu tumorskog metastaziranja. Moguće da je proteolitička konver-
zija netopivog (koreceptor vezan za membranu) u topivi oblik Sdc1, okidač skretanju proliferativne faze raka dojke u inva-
zivnu, što također može biti od dijagnostičko-terapijske koristi. Stromalna ekspresija Sdc1 znači ne samo jednostavnu fiksa-
ciju Sdc1 otpuštenog s epitelnih stanica na stromalne, nego i autohtonu sintezu Sdc1 u reaktivnim stromalnim fibroblastima. 
Interakcijom s heparin-vezujućim čimbenicima rasta, Sdc1 se kumulira u stromi invazivnih tumora čime doprinosi njenoj 
proliferaciji i neoangiogenezi. U više od 70% karcinoma dojke Sdc1 je induciran u stromalnim fibroblastima, uz značajnu 
razliku ekspresije Sdc1 između strome malignog i nemalignog tkiva dojke. Iako dio karcinoma dojke gubi Sdc1, kod većine 
je izražen ili prekomjerno izražen, a njegova ekspresija se veže uz slabiji odgovor tog karcinoma na kemoterapiju. Studije o 
prognostičkom značenju Sdc1 u karcinomu dojke pokazale su nejednake rezultate, što upućuje na potrebu za novim istraži-
vanjima na ovu temu.
KLJUČNE RIJEČI: dojka, karcinom, syndecan-1, imunohistokemija, izraženost
